Man Group
RXRX icon

Man Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Man Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.68M Buy
1,199,563
+1,171,603
+4,190% +$4.53M 0.01% 1309
2025
Q4 		$114K Buy
+27,960
New +$138K ﹤0.01% 2186
2025
Q1 		– Sell
-70,802
Closed -$479K – 2337
2024
Q4 		$479K Buy
+70,802
New +$476K ﹤0.01% 1684
2024
Q3 		– Sell
-27,971
Closed -$210K – 2173
2024
Q2 		$210K Buy
+27,971
New +$244K ﹤0.01% 1880
2023
Q1 		– Hold
0
– – – 1833
2022
Q4 		– Sell
-10,671
Closed -$114K – 2180
2022
Q3 		$114K Buy
+10,671
New +$108K ﹤0.01% 1841

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Man Group's RXRX Position: Q1 2026 in Review

Man Group increased its Recursion Pharmaceuticals (RXRX) stake by 4,190% in Q1 2026, buying an estimated $4.53M and bringing the position to 1,199,563 shares worth $3.68M. The position accounts for 0.01% of the portfolio, ranked #1309.

Man Group first reported a position in RXRX in Q3 2022 and has held it in 5 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Man Group held 1,199,563 shares of Recursion Pharmaceuticals worth $3.68M as of Q1 2026.
  • Man Group bought 1,171,603 Recursion Pharmaceuticals shares in Q1 2026, an estimated $4.53M.
  • Recursion Pharmaceuticals made up 0.01% of Man Group's portfolio in Q1 2026, its #1309 holding.
  • Man Group first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 5 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.